Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatol Commun
Main Authors: Kruger, Annie J., Fuchs, Bryan C., Masia, Ricard, Holmes, Jacinta A., Salloum, Shadi, Sojoodi, Mozhdeh, Ferreira, Diego S., Rutledge, Stephanie M., Caravan, Peter, Alatrakchi, Nadia, Vig, Pam, Lefebvre, Eric, Chung, Raymond T.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944590/
https://ncbi.nlm.nih.gov/pubmed/29761169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1160
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados